Primer: Santen Pharmaceutical (4536 JP) - Aug 2026
Santen Pharmaceutical is a specialized ophthalmology company poised for an inflection point in FY27, driven by strategic expansion into...
100 Views
APAC Healthcare Weekly (Sept 20) –Sino Bio, Impact Therapeutics, Takeda, Daiichi Sankyo, SK Biopharm
NMPA accepted Sino Bio’s NDA for bispecific ADC drug candidate. FDA granted priority review to Takeda’s zasocitinib for moderate-to-severe plaque...
92 Views
Santen Pharma (4536 JP): China Recovery in FY26, FY27 To Be Inflection Point with Overseas and R&D
​Santen Pharmaceutical sees FY26 revenue drop but net profit rises. Expects FY27 growth to be driven by overseas business and will be an inflection...
139 Views
Santen Pharma (4536 JP): Asia (Ex-China) & EMEA Show Growth, R&D Progress Augur Well
​Santen Pharmaceutical sees revenue and profit decline in 9MFY26. Drug development, regular consistent approvals and market leadership position...
212 Views
Sohn Tokyo Preview: TriVista’s Masaki Gotoh – What Traditional Stock Pickers Often Miss, and More
The inaugural Sohn Tokyo conference is coming up on Oct. 16 at the Roppongi Hills Club. One of this year’s co-hosts and speakers is Masaki Gotoh...
129 Views